Evaluating Jia Shen Tablets for Chronic Heart Failure

A Open Label, Standardise-loaded and Single-Centre Phase Ⅰb Clinical Trial：Pharmacokinetic and Pharmacodynamic of Jia Shen Tablets in Chronic Heart Failure

This study is testing if Jia Shen Tablets, a traditional Chinese medicine, can help people with chronic heart failure feel better and stay safe while using it.

Quick facts

• Phase: PHASE1
• Study type: Interventional
• Enrollment: 18 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: Tasly Pharmaceutical Group Co., Ltd (industry)
• Locations: 1 site (Tianjin, Tianjin Municipality)
• Trial ID: NCT06348498 on ClinicalTrials.gov

What this trial studies

This clinical trial aims to assess the pharmacokinetic and pharmacodynamic properties of Jia Shen Tablets, a traditional Chinese medicine, in patients suffering from chronic heart failure. It is an open-label, standardized, single-center Phase 1b trial focusing on patients with coronary heart disease and specific traditional Chinese medicine classifications. The study will also preliminarily evaluate the efficacy and safety of the treatment in this patient population.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18-75 with chronic heart failure and specific traditional Chinese medicine classifications.

Not a fit: Patients with acute heart failure or other specific heart conditions may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could offer a new therapeutic option for patients with chronic heart failure.

How similar studies have performed: While this approach is based on traditional Chinese medicine, similar studies have shown promise in evaluating herbal treatments for chronic conditions, though this specific formulation is novel.

Eligibility criteria

Inclusion Criteria:

* Age 18-75 years, either sex;
* Meet the diagnostic criteria for CHD and CHF;
* Meet the TCM differentiation criteria of yang deficiency and blood stasis in CHF;
* LVEF \< 40% (Modified Simpson's Method);
* Class II to IⅢ for NYHA functional classification;
* Receive Steady dose of standard medication for CHF for at least 2 weeks;
* Understand the research requirements and are willing to provide written informed consent.

Exclusion Criteria:

* Acute heart failure or acute exacerbation of chronic heart failure;
* HF caused by other heart diseases, such as congenital heart disease, severe stenosis or insufficiency of heart valves, cardiomyopathy (e.g., hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy, dilated cardiomyopathy, alcoholic cardiomyopathy), moderate massive pericardial effusion, constrictive pericarditis, infective endocarditis;
* Patients with acute coronary syndrome within 30 days before receiving the trial drug，and the following situation within 6 months before receiving the trial drug，such as acute myocardial infarction，revascularization (e.g., PCI, CABG) or left ventricular reconstruction surgery, pacemaker implantation for cardiac resynchronization, and undergoing cardiothoracic surgery;
* Expect to receive an implantable device (e.g. ICD, CRT), or revascularization (e.g. PCI, CABG), or other cardiovascular surgery during the trial period;
* Severe arrhythmias \[e.g., ventricular tachycardia, second degree type II or higher sinus or atrioventricular block without pacemaker placement, QT interval (QTc) greater than 480 ms after heart rate adjustment according to Fridericia's formula, or known history or symptoms of long QT syndrome\];
* Combined with serious diseases of other systems, such as liver, kidney, hematopoietic system and other serious primary diseases, tumors, mental diseases, etc;
* The presence of uncontrolled hypertension (systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg), or the presence of hypotension (systolic blood pressure \< 80 mmHg and/or diastolic blood pressure \< 50 mmHg);
* ALT or AST more than 3 times the upper limit of normal, and/or estimated glomerular filtration rate (eGFR) \< 30 ml/min/1.73m2;
* Glycosylated hemoglobin (HbA1c) ≥9.0%, or fasting blood glucose ≥13.9 mmol/L;
* Anemia (Hb \< 110 g/L for women, Hb \< 120 g/L for men);
* Blood potassium is above the upper limit of normal;
* Patients who tested positive for five hepatitis B tests (except surface antibodies) or hepatitis C, or anti-TP or HIV antibodies;
* Patients with a history of drug abuse who test positive for drug abuse (morphine, methamphetamine, ketamine, dimethyldioxyamphetamine, THC, cocaine);
* Women who are pregnant or nursing, or have a need to have children within 3 months after the last dose of the trial;
* Participating in other studies and taking investigational drugs from other studies within 3 months prior to screening;
* Allergic to Jiashen tablets or their ingredients;
* Other situations judged by the researchers to be inappropriate for this study.

Where this trial is running

Tianjin, Tianjin Municipality

• The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine — Tianjin, Tianjin Municipality, China (RECRUITING)

Study contacts

• Study coordinator: Rui Liu

Conditions: Heart Failure